Science

$Deniz Can Guven: Toripalimab phase I data in refractory CCA$

Photo taken from Deniz Can Guven/X

Jan 28, 2025, 06:20

Deniz Can Guven: Toripalimab phase I data in refractory CCA

Deniz Can Guven, The Editorial Board Member of BMC Cancer and Medical Oncologist at Health Sciences University, shared a recent article by Amit Mahipal et al. on X:

“Toripalimab phase I data in refractory CCA:

The first study with Toripalimab in the US.
Manageable side effects.
Acceptable disease control (40%).
Could additional IO options improve access?

“Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study“

Authors: Amit Mahipal, Milind Javle, Judy Wang, Todd M. Bauer, David L. Bajor, Anthony D. Elias, Anthony Shields, Elizabeth Davis, Sant Chawla, Howard Safran, John D. Powderly, Gina D’Amato, Christian F. Meyer, Xiongwen Tang, Sheng Yao and Patricia Keegan

$Deniz Can Guven: Toripalimab phase I data in refractory CCA 1$

More posts featuring Deniz Can Guven.

Amit Mahipal cancer cholangiocarcinoma Christian F Meyer David L. Bajor Deniz Can Guven disease Judy Wang Milind Javle OncoDaily Oncology Patricia Keegan Sheng Yao Todd M Bauer Toripalimab phase I Xiongwen Tang

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term